Introduction to a cancer symposium for the practitioner

Mayo Clinic Proceedings

Volumn 80, Issue 8, 2005, Pages 1085-1086

  Tefferi, Ayalew ^a   Rajkumar, S Vincent ^a   Adjei, Alex A ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR;

ACUTE LEUKEMIA; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONFERENCE PAPER; DRUG TARGETING; FEMALE; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HODGKIN DISEASE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER; SOLID TUMOR;

EID: 23244457583     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.8.1085     Document Type: Conference Paper

References (23)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-488.
3. Twombly R. Cancer surpasses heart disease as leading cause of death for all but the very elderly. J Natl Cancer Inst. 2005;97:330-331.
4. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91-113.
5. Tomida S, Yatabe Y, Yanagisawa K, Mitsudomi T, Takahashi T. Throwing new light on lung cancer pathogenesis: updates on three recent topics. Cancer Sci. 2005;96:63-68.
6. Lynch JP, Hoops TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am. 2002;16:775-810.
7. Chen Z, Sandberg AA. Molecular cytogenetic aspects of hematological malignancies: clinical implications. Am J Med Genet. 2002;115:130-141.
8. Dumitrescu RG, Cotarla I. Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med. 2005;9:208-221.
9. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18:768-780.
10. Tallman MS. Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol. 2004;41(2, suppl 4):27-32.
11. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-214.
12. V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947-958.
13. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
14. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
15. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
16. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993; 92:1736-1744.
17. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002;16:1207-1212.
18. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
19. Pardanani A, Tefferi A. Imaunib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104:1931-1939.
20. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001;28(5, suppl 17):19-26.
21. Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol. 2004;31(1, suppl 2):7-11.
22. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-2501.
23. Tefferi A, Bolander ME, Ansell SM, Wieben ED, Spelsberg TC. Primer on medical genomics, part III: microarray experiments and data analysis. Mayo Clin Proc. 2002;77:927-940.